Table 3.
Clinical and demographic characteristics of the matched patients with multidrug resistant Acinetobacter baumannii pneumonia treated with colistin or tigecycline
| Characteristics | Colistin N = 84 | Tigecycline N = 84 | p -value |
|---|---|---|---|
| Age |
63.8 (19.8) |
63.5 (17.7) |
.92 |
| Male |
63 (75) |
65 (77.4) |
.67 |
| APACHE II score |
21.6 (9.4) |
22.0 (8.8) |
.99 |
| Ventilator-associated pneumonia |
58 (69.1) |
60 (71.4) |
.74 |
| Early onset VAP |
6 (10.3) |
4 (6.7) |
.38 |
| Late onset VAP |
52 (90.0) |
56 (93.3) |
|
| Length of hospital stay before enrollment |
29.5 (33.7) |
29.0 (30.1) |
.92 |
| Length of ICU stay before enrollment |
20.2 (29.6) |
18.5 (17.9) |
.56 |
| Duration of treatment |
14.0 (11.2) |
12.9 (9.3) |
.51 |
| Cardiovascular disease |
15 (17.9) |
15 (17.9) |
1.00 |
| Diabetes mellitus |
24 (28.6) |
27 (32.1) |
.59 |
| Insulin use |
20 (23.8) |
21 (25) |
.85 |
| Chronic kidney disease |
22 (26.2) |
22 (26.2) |
1.00 |
| Liver cirrhosis |
2 (2.4) |
4 (4.8) |
.41 |
| Chronic pulmonary disease |
8 (9.5) |
8 (9.5) |
1.00 |
| Malignancy |
2 (2.4) |
2 (2.4) |
1.00 |
| Autoimmune |
3 (3.6) |
5 (6.0) |
.48 |
| Operation history |
40 (47.6) |
45 (53.6) |
.44 |
| Combination therapy |
|
|
|
| Aminoglycoside |
1 (1.2) |
2 (2.4) |
.56 |
| Carbapenem |
9 (10.7) |
9 (10.7) |
1.00 |
| Sulbactam |
1 (1.2) |
3 (3.6) |
.32 |
| Baseline creatine (mg/dL) |
1.70 (1.40) |
1.81 (1.60) |
.50 |
| Propensity score | 0.370 (0.130) | 0.370 (0.131) | .97 |
APACHE II, acute physiology and chronic health evaluation II; ICU, intensive care units; VAP, ventilator-associated pneumonia.